Forewarned is forearmed: erythropoietin use in CKD patients with cancer
- PMID: 24052466
- DOI: 10.5301/jn.5000334
Forewarned is forearmed: erythropoietin use in CKD patients with cancer
Abstract
Nayak-Rao and McCormick raise important concerns about erythropoietin use in patients with chronic kidney disease and cancer, and appropriately build a case for caution in this setting (J Nephrol. 2013, in press). Their comprehensive and insightful review highlights both the clinical and the basic science considerations that form the basis for this warning.
Comment on
-
Erythropoietin use in CKD patients with cancer: to tread with caution?J Nephrol. 2013 Sep-Oct;26(5):829-35. doi: 10.5301/jn.5000316. Epub 2013 Sep 18. J Nephrol. 2013. PMID: 24052463 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical